Role of Estrogen Receptor Binding and Transcriptional Activity in the Stimulation of Hyperestrogenism and Nuclear Bodies

Total Page:16

File Type:pdf, Size:1020Kb

Role of Estrogen Receptor Binding and Transcriptional Activity in the Stimulation of Hyperestrogenism and Nuclear Bodies Proc. Natl. Acad. Sci. USA Vol. 75, No. 6, pp. 2781-2784, June 1978 Cell Biology Role of estrogen receptor binding and transcriptional activity in the stimulation of hyperestrogenism and nuclear bodies (nuclear morphology/nafoxidine/estradiol) JAMES H. CLARK*, JAMES W. HARDIN*, HELEN A. PADYKULAt, AND CONSTANCE A. CARDASISt eDepartment of Cell Biology, Baylor College of Medicine, Houston, Texas 77030; and t Laboratory of Electron Microscopy, Wellesley College, Wellesley, Maschusetts 02181 Communicated by Elwood V. Jensen, March 15,1978 ABSTRACT The effects of estradiol and nafoxidine on nu- MATERIALS AND METHODS clear estrogen receptor binding, RNA polymerase activities, and Animals. Immature (21 days old) female rats of the uterine ultrastructure were studied. Animals were either in- jected with estradiol, implanted with estradiol/paraffin pellets, Sprague-Dawley strain were obtained from Texas Inbred or injected with nafoxidine. Animals treated with nafoxidine Mouse Co. (Houston, TX). Animals were kept in a controlled or estradiol implants showed sustained long-term nuclear re- environment (22°; constant relative humidity; light/dark cycle tention of estrogen receptor and increased nuclear RNA poly- of 12 hr each with the light cycle starting at 0700), and food and merase activities for up to 72 hr. A single injection of estradiol water were provided ad lib. caused initial increases in these variables which returned to Estradiol was dissolved in 0.9% NaCl/1% ethanol, and control levels by 24 hr after hormone treatment. Uterine tissue nafoxidine was dissolved 1% ethanol in distilled water. Alter- was examined by light and electron microscopy 72 hr after hormone treatments. Uteri from either estradiol-implanted or natively, 50-mg paraffin implants were prepared containing nafoxidine-treated animals showed markedly increased hy- 10% (wt/wt) estradiol by liquifying a known quantity of par- pertrophy of the luminal epithelial cells. Nuclei in sections of affin, mixing the appropriate quantity of hormone with it, and the uteri of these hyperestrogenized animals displayed a large dropping a uniform volume of the liquid mixture onto a pre- number and wide array of nuclear bodies composed of a fila- cooled glass surface (9). mentous capsule and granular cores. We conclude that hyp Vehicle (0.25 ml), estradiol (1.0 Ag), or nafoxidine (50,ug) was erestrogenization, a condition that eventually results in ab- administered subcutaneously at various times prior to sacrifice. normal cell growth, is correlated with increased and sustained nuclear binding of the estrogen receptor, increased and sus- In experiments involving implants, animals were placed under tained RNA polymerase activity, and the appearance of nuclear light ether anesthesia, a small incision was made in the nape of bodies. the neck, a paraffin implant was placed subcutaneously, and the incision was closed with one or two sutures. The nonsteroidal estrogen antagonist nafoxidine is an atypical Animals were sacrificed by cervical dislocation. The uteri long-acting estrogen in the immature rat. An injection of were rapidly removed, stripped of adhering fat, weighed, and nafoxidine causes the translocation of the estrogen receptor placed in either ice-cold 0.9% NaCl/5 mM ethylene glycol- from the cytoplasm to the nucleus of uterine cells with a sub- bis(fi-aminoethyl ether)-N,N'-tetraacetic acid for nuclear iso- sequent long-term nuclear retention of the receptor, presum- lation or in the appropriate fixative for morphological exami- ably as a receptor-nafoxidine complex. This long-term nuclear nation (see below). retention of the receptor is accompanied by sustained stimu- Isolation of Nuclei. Nuclei were isolated by a modification lation of uterine size and long-term increase of nuclear RNA of the hexylene glycol procedure as described (5). polymerase activities (1-5). A single injection of the physio- Assay of Endogenous RNA Polymerase Activities. Total logical hormone 17,B-estradiol also results in nuclear retention endogenous nuclear RNA polymerase activities were measured of the receptor, stimulation of uterine hypertrophy, and in- by the addition of an aliquot of nuclei (usually 5-15 ,g of DNA) crease of nuclear RNA polymerase activities but these effects to a tube that contained 2.5 Mmol of Tris-HCl (pH 8.0), 0.05 are of a much shorter duration than those observed after Mumol of MnC12, 0.1 Mmol of MgCl2, 3 ,mol of (NH4)2SO4, 0.1 nafoxidine administration (1-7). ,4mol of dithiothreitol, 0.03 umol each of ATP, CTP and GTP, It has recently been shown that a single injection of nafoxi- 3 nmol of unlabeled UTP, and 2.5 ,Ci of [3H]UTP (12-16 Ci/ dine or Clomid, a closely related compound, in neonatal rats mmol) in a final volume of 50 ,l. a-Amanitin was used to de- causes hyperestrogenization of the reproductive tract which termine the amount of activity due to RNA polymerase II. RNA results in the appearance of multiple abnormalities and tumors polymerase I activity was determined by subtraction of the in the adult animal (8). a-amanitin-inhibited activity from the total (5). Reactions were To relate and extend the above biochemical and histo- incubated at 300 for 20 min and terminated by removing a pathological observations to morphological changes that occur 25-Ml aliquot from each reaction and spotting it on a 2.5-cm in the normal immature rat uterus in response to nafoxidine and DE-81 filter paper disc. The disc was immediately transferred estradiol treatment, we examined the ultrastructure of uterine to a wash solution of 0.5 M Na2HPO4. Filters were washed and luminal epithelial cells as well as changes in nuclear RNA assayed for radioactivity as described by Roeder (10). polymerase activities after long-term exposure to these com- DNA Determination. DNA was estimated by the diphe- pounds. nylamine method of Burton (11). Measurement of Nuclear Estrogen Receptors. The level The costs of publication of this article were defrayed in part by the of nuclear estrogen receptors was measured by the [3H]estradiol payment of page charges. This article must therefore be hereby marked exchange assay as described (12). "advertisement" in accordance with 18 U. S. C. §1734 solely to indicate Fixation and Sectioning Procedures for Light and Electron this fact. Microscopy. Uterine cross sections (1-2 mm thick) were ini- 2781 Downloaded by guest on October 1, 2021 2782 Cell Biology: Clark et al. Proc. Natl. Acad. Sci. USA 75 (1978) 1.5 C 400 o x 300 1.0E40.m 0 < uz .c0 0 cm 200 a)X e2 0.5 a) fnI al100 a) - z Time, hr FIG. 1. Relationship of nuclear binding of receptor-estrogen complex to endogenous RNA polymerase activities. Immature rats were either injected with 1 gg of estradiol (A), implanted with an estradiol/paraffm pellet (B), or injected with 50 ug of nafoxidine (C). At the indicated times, animals were sacrificed, uteri were removed, and nuclei were isolated. Each point represents the mean of six determinations. 0, Recep- tor-estrogen complex; ,, RNA polymerase I; 0, RNA polymerase II. tially fixed for 2 hr at room temperature in one of two aldehydic the nuclear retention of the estrogen receptor. To define further mixtures: (i) 2% glutaraldehyde 2% formaldehyde/picric acid the relationship of nuclear retention of estrogen receptor and (13) or (ii) 4% glutaraldehyde/1% formaldehyde (14, 15). After the stimulation of uterine endogenous RNA polymerase ac- rinsing in 0.1 M sodium cacodylate/0.25 M sucrose, pH 7.4, tivities, animals were either injected with estradiol or nafoxidine they were treated with 1% OS04 in barbital/acetate buffer, or implanted with estradiol and sacrificed at 24-hr intervals. dehydrated, and embedded in Epon. Semithin (0.75 Mim) and Nafoxidine-treated and estradiol-implanted animals showed ultrathin sections were prepared on a Sorvall MT-2 ultrami- increased and sustained levels of RNA polymerase activities at sections were stained with 0.25% toluidine all times examined (Fig. 1). In contrast, estradiol injection crotome. Semithin caused increased levels of polymerase activities by 12 hr with blue in 0.25% borax. Ultrathin sections were stained with uranyl a return to control levels by 24 hr. These alterations in poly- acetate and lead hydroxide and were examined in a Siemens merase activities closely parallel levels of nuclear estrogen re- 1A electron microscope. ceptors. To relate the above biochemical observations to morpho- RESULTS logical changes that occur in the normal immature rat uterus Previous results (5) from this laboratory had demonstrated that in response to nafoxidine and estradiol, samples of uteri treated a single injection of either nafoxidine or estradiol to immature as above were prepared for light and electron microscopy. The rats stimulated endogenous nuclear RNA polymerase activities. ultrastructure of the uterine luminal epithelial cells was ex- The extent and the degree of stimulation were correlated with amined in these samples. The height of the luminal epithelial A B C D FIG. 2. Imnmature rat uterine luminal epithelium and stroma 72 hr after treatment with estradiol or nafoxidine. (A) Injected with saline; (B) injected with 1 ug of estradiol; (C) implanted with estradiol/paraffi pellets; (D) injected withsg50 of nafoxidine. (Epon sections, 1 Mm; toluidine blue; X500.) Downloaded by guest on October 1, 2021 Cell Biology: Clark et al. Proc. Natl. Acad. Sci. USA 75 (1978) 2783 *aeuA.# '.s*s'.'A''t* at.*,Do V4 OA.~ ~ .A *S- k. t _s £ S.;~~~~~~~~~~~~~~~V , , s et;tAN ?t *tid44 v Rt V ihS 464~~~~~~~~~~~~~~. FIG. 3. Nuclear bodies in the uterine luminal epithelial cells of immature rats 72 hr after a single injection of 50 gsg of nafoxidine. In these two profiles ofluminal epithelial nuclei, three nuclear bodies are apparent in the left nucleus and two in the right (arrows). (Insets A-D) Principal forms of the nuclear bodies observed after nafoxidine injection or estradiol implantation: (A) singlet (filamentous capsule and less-dense core); (B) granular nuclear body (small granules in core); (C) doublet (double core); (D) granular nuclear body with large electron-opaque inclusions.
Recommended publications
  • Wo 2009/082437 A9
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) CORRECTED VERSION (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date 2 July 2009 (02.07.2009) WO 2009/082437 A9 (51) International Patent Classification: KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, C07D 207/08 (2006.01) A61K 31/402 (2006.01) MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, C07D 207/09 (2006.01) A61P 5/26 (2006.01) NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, C07D 498/04 (2006.01) SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (21) International Application Number: PCT/US2008/013657 (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, (22) International Filing Date: G M M N S D S L s z τ z U G Z M 12 December 2008 (12.12.2008) z w Eurasian (A M B γ KG> M D RU> τ (25) Filing Language: English TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, (26) Publication Language: English M C M T N L N O P L P T R O S E S I s T R OAPI (30) Priority Data: B F ' B J ' C F ' C G ' C I' C M ' G A ' G N ' 0 G W ' M L ' M R ' 61/008,731 2 1 December 2007 (21 .12.2007) US N E ' S N ' T D ' T G ) - (71) Applicant (for all designated States except US): LIG- Declarations under Rule 4.17: AND PHARMACEUTICALS INCORPORATED [US/ — as to applicant's entitlement to apply for and be granted US]; 11085 N.
    [Show full text]
  • The Effects of Androgens and Antiandrogens on Hormone Responsive Human Breast Cancer in Long-Term Tissue Culture1
    [CANCER RESEARCH 36, 4610-4618, December 1976] The Effects of Androgens and Antiandrogens on Hormone responsive Human Breast Cancer in Long-Term Tissue Culture1 Marc Lippman, Gail Bolan, and Karen Huff MedicineBranch,NationalCancerInstitute,Bethesda,Maryland20014 SUMMARY Information characterizing the interaction between an drogens and breast cancer would be desirable for several We have examined five human breast cancer call lines in reasons. First, androgens can affect the growth of breast conhinuous tissue culture for andmogan responsiveness. cancer in animals. Pharmacological administration of an One of these cell lines shows a 2- ho 4-fold stimulation of drogens to rats bearing dimathylbenzanthracene-induced thymidina incorporation into DNA, apparent as early as 10 mammary carcinomas is associated wihh objective humor hr following androgen addition to cells incubated in serum regression (h9, 22). Shionogi h15 cells, from a mouse mam free medium. This stimulation is accompanied by an ac many cancer in conhinuous hissue culture, have bean shown celemation in cell replication. Antiandrogens [cyproterona to be shimulatedby physiological concentrations of andro acetate (6-chloro-17a-acelata-1,2a-methylena-4,6-pregna gen (21), thus suggesting that some breast cancer might be diene-3,20-dione) and R2956 (17f3-hydroxy-2,2,1 7a-tnima androgen responsive in addition to being estrogen respon thoxyastra-4,9,1 1-Inane-i -one)] inhibit both protein and siva. DNA synthesis below control levels and block androgen Evidence also indicates that tumor growth in humans may mediahed stimulation. Prolonged incubahion (greahenhhan be significantly altered by androgens. About 20% of pahianhs 72 hn) in antiandrogen is lethal.
    [Show full text]
  • Alpha-Fetoprotein: the Major High-Affinity Estrogen Binder in Rat
    Proc. Natl. Acad. Sci. USA Vol. 73, No. 5, pp. 1452-1456, May 1976 Biochemistry Alpha-fetoprotein: The major high-affinity estrogen binder in rat uterine cytosols (rat alpha-fetoprotein/estrogen receptors) JOSE URIEL, DANIELLE BOUILLON, CLAUDE AUSSEL, AND MICHELLE DUPIERS Institut de Recherches Scientifiques sur le Cancer, Boite Postale No. 8, 94800 Villejuif, France Communicated by Frangois Jacob, February 3, 1976 ABSTRACT Evidence is presented that alpha-fetoprotein nates in hypotonic solutions, whereas in salt concentrations (AFP), a serum globulin, accounts mainly, if not entirely, for above 0.2 M the 4S complex is by far the major binding enti- the high estrogen-binding properties of uterine cytosols from immature rats. By the use of specific immunoadsorbents to ty. AFP and by competitive assays with unlabeled steroids and The relatively high levels of serum AFP in immature rats pure AFP, it has been demonstrated that in hypotonic cyto- prompted us to explore the contribution of AFP to the estro- sols AFP is present partly as free protein with a sedimenta- gen-binding capacity of uterine homogenates. The results tion coefficient of about 4-5 S and partly in association with obtained with specific anti-AFP immunoadsorbents (12, 13) some intracellular constituent(s) to form an 8S estrogen-bind- provided evidence that at low salt concentrations,'AFP ac-' ing entity. The AFP - 8S transformation results in a loss of antigenic reactivity to antibodies against AFP and a signifi- counts for most of the estrogen-binding capacity associated cant change in binding specificity. This change in binding with the 4-5S macromolecular complex.
    [Show full text]
  • Synthesis of Lasofoxifene, Nafoxidine and Their Positional Isomers Via the Novel Three-Component Coupling Reaction
    Molecules 2010, 15, 6773-6794; doi:10.3390/molecules15106773 OPEN ACCESS molecules ISSN 1420-3049 www.mdpi.com/journal/molecules Article Synthesis of Lasofoxifene, Nafoxidine and Their Positional Isomers via the Novel Three-Component Coupling Reaction Kenya Nakata, Yoshiyuki Sano and Isamu Shiina * Department of Applied Chemistry, Faculty of Science, Tokyo University of Science, 1-3 Kagurazaka, Shinjuku-ku, Tokyo 162-8601, Japan * Author to whom correspondence should be addressed; E-Mail: [email protected]; Fax: +81-3-3260-5609. Received: 21 August 2010; in revised form: 13 September 2010 / Accepted: 20 September 2010/ Published: 28 September 2010 Abstract: A Lewis acid-mediated three-component coupling reaction was successfully applied for the synthesis of lasofoxifene (1), nafoxidine (2), and their positional isomers, inv-lasofoxifene (3) and inv-nafoxidine (4). In the presence of HfCl4, the desired one-pot coupling reaction among 4-pivaloyloxybenzaldehyde (5), cinnamyltrimethylsilane (6), and anisole proceeded to afford the corresponding 3,4,4-triaryl-1-butene 7 in high yield. The iodocarbocyclization of the coupling product and the successive elimination of hydrogen iodide forming the olefin part, followed by the migration of the double-bond afforded the common synthetic intermediate of lasofoxifene (1) and nafoxidine (2) via a very concise procedure. Additionally, the syntheses of their positional isomers inv-lasofoxifene (3) and inv-nafoxidine (4) were also achieved through very convenient protocols. Keywords: three-component coupling reaction; diversity oriented synthesis; lasofoxifene; nafoxidine; inv-lasofoxifene; inv-nafoxidine 1. Introduction Multi-component coupling reactions (MCRs) are one of the most important tools in organic synthesis for the divergent production of bioactive molecules and highly complicated natural products [1-3].
    [Show full text]
  • Topical Administration of Toremifene and Its
    Patentamt |||| ||| 1 1|| ||| ||| ||| ||| || || || ||| |||| || JEuropaischesJ European Patent Office Office europeen des brevets (11) EP 0 633 774 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) int. CI.6: A61 K 31/135, A61K9/70, of the grant of the patent: ^g-| ^ 47/48 17.02.1999 Bulletin 1999/07 (86) International application number: ..... - ......„,,„number: 93906654.4 , (21) Application PCT/FI93/001 1 9 (22) Date of filing: 25.03.1993 x ' 3 (87)/Q-,X International, , ,..... publication ,.. number: WO 93/19746 (14.10.1993 Gazette 1993/25) (54) TOPICAL ADMINISTRATION OF TOREMIFENE AND ITS METABOLITES TOPISCH ANWENDBARE ARZNEIMITTEL, ENTHALTEND TOREMIFEN UND DESSEN METABOLITE ADMINISTRATION TOPIQUE DE TOREMIFENE ET DE SES METABOLITES (84) Designated Contracting States: • KURKELA, Kauko Oiva Antero AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL 02180 Espoo (Fl) PTSE (74) Representative: (30) Priority: 03.04.1992 GB 9207437 Sexton, Jane Helen et al J.A. KEMP & CO. (43) Date of publication of application: 14 South Square 18.01.1995 Bulletin 1995/03 Gray's Inn London WC1 R 5LX (GB) (73) Proprietor: ORION-YHTYM A OY 02200 Espoo (Fl) (56) References cited: EP-A- 0 095 875 US-A- 4 990 538 (72) Inventors: • DEGREGORIO, Michael, William Granite Bay, CA 95746 (US) CO r»- r»- co CO Note: Within nine months from the publication of the mention of the grant of the European patent, give CO any person may notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in o a written reasoned statement.
    [Show full text]
  • In Vitro and in Silico Analyses of the Inhibition of Human Aldehyde Oxidase By
    JPET Fast Forward. Published on July 9, 2019 as DOI: 10.1124/jpet.119.259267 This article has not been copyedited and formatted. The final version may differ from this version. JPET #259267 In Vitro and In Silico Analyses of the Inhibition of Human Aldehyde Oxidase by Bazedoxifene, Lasofoxifene, and Structural Analogues Shiyan Chen, Karl Austin-Muttitt, Linghua Harris Zhang, Jonathan G.L. Mullins, and Aik Jiang Lau Downloaded from Department of Pharmacy, Faculty of Science, National University of Singapore, Singapore jpet.aspetjournals.org (S.C., A.J.L.); Institute of Life Science, Swansea University Medical School, United Kingdom (K.A-M, J.G.L.M.); NanoBioTec, LLC., Whippany, New Jersey, U.S.A. (L.H.Z.); at ASPET Journals on September 29, 2021 Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore (A.J.L.) 1 JPET Fast Forward. Published on July 9, 2019 as DOI: 10.1124/jpet.119.259267 This article has not been copyedited and formatted. The final version may differ from this version. JPET #259267 Running Title In Vitro and In Silico Analyses of AOX Inhibition by SERMs Corresponding author: Dr. Aik Jiang Lau Department of Pharmacy, Faculty of Science, National University of Singapore, 18 Science Drive 4, Singapore 117543. Downloaded from Tel.: 65-6601 3470, Fax: 65-6779 1554; E-mail: [email protected] jpet.aspetjournals.org Number of text pages: 35 Number of tables: 4 Number of figures: 8 at ASPET Journals on September 29, 2021 Number of references 60 Number of words in Abstract (maximum
    [Show full text]
  • Kinetic Analysis of Estrogen Receptor Ligand Interactions
    Kinetic analysis of estrogen receptor͞ ligand interactions Rebecca L. Rich*, Lise R. Hoth†, Kieran F. Geoghegan†, Thomas A. Brown†, Peter K. LeMotte†, Samuel P. Simons†, Preston Hensley†, and David G. Myszka*‡ *Center for Biomolecular Interaction Analysis, University of Utah, Salt Lake City, UT 84132; and †Pfizer Global Research and Development, Eastern Point Road, Groton, CT 06340 Communicated by Pamela J. Bjorkman, California Institute of Technology, Pasadena, CA, May 14, 2002 (received for review February 18, 2002) Surface plasmon resonance biosensor technology was used to receptor͞ligand interactions. In a qualitative screening mode, directly measure the binding interactions of small molecules to the receptor binders and nonbinders were identified. In a quantita- ligand-binding domain of human estrogen receptor. In a screening tive high-resolution mode, precise kinetic and affinity parame- mode, specific ligands of the receptor were easily discerned from ters were obtained for compounds across a wide dynamic range. nonligands. In a high-resolution mode, the association and disso- These mechanistic data complement static structural informa- ciation phase binding responses were shown to be reproducible tion about ER (10–14), revealing how radically different rate and could be fit globally to a simple interaction model to extract constants govern the binding of agonist and selected antagonist reaction rate constants. On average, antagonist ligands (such as ligands. tamoxifen and nafoxidine) were observed to bind to the receptor with association rates that were 500-fold slower than agonists Methods (such as estriol and ␤-estradiol). This finding is consistent with Reagents. Ligand-binding domains of human ER-␣ and -␤ were these antagonists binding to an altered conformation of the expressed in Escherichia coli as His-tagged proteins and purified receptor.
    [Show full text]
  • Analytics for Improved Cancer Screening and Treatment John
    Analytics for Improved Cancer Screening and Treatment by John Silberholz B.S. Mathematics and B.S. Computer Science, University of Maryland (2010) Submitted to the Sloan School of Management in partial fulfillment of the requirements for the degree of Doctor of Philosophy in Operations Research at the MASSACHUSETTS INSTITUTE OF TECHNOLOGY September 2015 ○c Massachusetts Institute of Technology 2015. All rights reserved. Author................................................................ Sloan School of Management August 10, 2015 Certified by. Dimitris Bertsimas Boeing Leaders for Global Operations Professor Co-Director, Operations Research Center Thesis Supervisor Accepted by . Patrick Jaillet Dugald C. Jackson Professor Department of Electrical Engineering and Computer Science Co-Director, Operations Research Center 2 Analytics for Improved Cancer Screening and Treatment by John Silberholz Submitted to the Sloan School of Management on August 10, 2015, in partial fulfillment of the requirements for the degree of Doctor of Philosophy in Operations Research Abstract Cancer is a leading cause of death both in the United States and worldwide. In this thesis we use machine learning and optimization to identify effective treatments for advanced cancers and to identify effective screening strategies for detecting early-stage disease. In Part I, we propose a methodology for designing combination drug therapies for advanced cancer, evaluating our approach using advanced gastric cancer. First, we build a database of 414 clinical trials testing chemotherapy regimens for this cancer, extracting information about patient demographics, study characteristics, chemother- apy regimens tested, and outcomes. We use this database to build statistical models to predict trial efficacy and toxicity outcomes. We propose models that use machine learning and optimization to suggest regimens to be tested in Phase II and III clinical trials, evaluating our suggestions with both simulated outcomes and the outcomes of clinical trials testing similar regimens.
    [Show full text]
  • In the Prepubertal Rat P
    Effect of neonatal exposure to the antioestrogens nafoxidine and CI-628 upon the development of the uterus in the prepubertal rat P. S. Campbell and P. M. Satterfield Department of Biological Sciences, The University of Alabama in Huntsville, Huntsville, AL 35899, U.S.A. Summary. Neonatal Sprague\p=n-\Dawleyrats were injected with the antioestrogens nafoxidine or CI-628 on Day 3 of life alone or in combination with oestradiol benzoate 24 h later. Oestrogen-stimulated glucose oxidation and cytoplasmic oestrogen binding sites of the uteri were assessed at 21\p=n-\23days of age. Neither antioestrogen antagonized the prepubertal uterine impairments produced by neonatal oestradiol treatment. Both antioestrogens administered alone produced deficits which mimicked those produced by neonatal oestrogenization. However, the agonist property of each antioestrogen was differentially expressed: treatment with CI-628 reduced prepubertal oestrogen binding sites in the uterus, but nafoxidine exposure decreased the sensitivity of the uterus to oestradiol stimulation of glucose oxidation. It is postulated that CI-628 directly affects the uterus to reduce production of oestrogen receptor protein, while nafoxidine affects the development of the uterine phosphogluconate oxidative pathway indirectly through impaired ovarian function. However, antioestrogens blocked the neonatal oestradiol-induced reduction in the oestrogen-stimulated production of actomyosin in the adult uterus. Therefore, while both CI-628 and nafoxidine are clearly agonists in the neonatal rat, each appears to exhibit cell-specific agonist and antagonist properties. Keywords: uterus; antioestrogen; oestrogen receptor; glucose metabolism; neonate; rat Introduction It has been previously demonstrated (Geliert et al, 1977; Campbell, 1980) that neonatal adminis¬ tration of oestradiol benzoate results in impaired uterine growth responses to exogenous oestradiol in the prepubertal rat.
    [Show full text]
  • Estrogens and Antiestrogens Stimulate Release of Bone Resorbing Activity by Cultured Human Breast Cancer Cells
    Estrogens and antiestrogens stimulate release of bone resorbing activity by cultured human breast cancer cells. A Valentin-Opran, … , S Saez, G R Mundy J Clin Invest. 1985;75(2):726-731. https://doi.org/10.1172/JCI111753. Research Article Patients with advanced breast cancer may develop acute, severe hypercalcemia when treated with estrogens or antiestrogens. In this study, we examined the effects of estrogens and related compounds on the release of bone resorbing activity by cultured human breast cancer cells in vitro. We found that the estrogen receptor positive breast cancer cell line MCF-7 releases bone resorbing activity in response to low concentrations of 17 beta-estradiol. Bone resorbing activity was also released in response to the antiestrogen nafoxidine. Other steroidal compounds had no effect on the release of bone resorbing activity. Estrogen-stimulated release of bone resorbing activity occurred with live bone cultures, but not with devitalized bones, indicating that the effect was bone cell mediated. The breast cancer cell line MDA-231, which does not have estrogen receptors, did not release bone resorbing activity in response to 17 beta- estradiol or nafoxidine. Release of the bone resorbing activity by MCF-7 cells incubated with 17 beta-estradiol was inhibited by indomethacin (10 microM) and flufenamic acid (50 microM), two structurally unrelated compounds that inhibit prostaglandin synthesis. Concentrations of 17 beta-estradiol and nafoxidine that caused increased release of bone resorbing activity by the breast cancer cells caused a four- to fivefold increase in release of prostaglandins of the E series by MCF-7 cells. These data may explain why some patients with advanced breast cancer […] Find the latest version: https://jci.me/111753/pdf Estrogens and Antiestrogens Stimulate Release of Bone Resorbing Activity by Cultured Human Breast Cancer Cells Alexandre Valentin-Opran, Gabriel Eilon, Simone Saez, and Gregory R.
    [Show full text]
  • Pharmacology of Estrogens and Progestogens: Influence of Different Routes of Administration
    CLIMACTERIC 2005;8(Suppl 1):3–63 Pharmacology of estrogens and progestogens: influence of different routes of administration H. Kuhl Department of Obstetrics and Gynecology, J. W. Goethe University of Frankfurt, Germany Key words: ESTROGENS, PROGESTOGENS, PHARMACOKINETICS, PHARMACODYNAMICS, HORMONE REPLACEMENT THERAPY ABSTRACT This review comprises the pharmacokinetics and pharmacodynamics of natural and synthetic estrogens and progestogens used in contraception and therapy, with special consideration of hormone replacement therapy. The paper describes the mechanisms of action, the relation between structure and hormonal activity, differences in hormonal pattern and potency, peculiarities in the properties of certain steroids, tissue-specific effects, and the metabolism of the available estrogens and progestogens. The influence of the route of administration on pharmacokinetics, hormonal activity and metabolism is presented, and the effects of oral and transdermal treatment with estrogens on tissues, clinical and serum parameters are compared. The effects of oral, transdermal (patch and gel), intranasal, sublingual, buccal, vaginal, subcutaneous and intramuscular adminis- tration of estrogens, as well as of oral, vaginal, transdermal, intranasal, buccal, intramuscular and intrauterine application of progestogens are discussed. The various types of progestogens, their receptor interaction, hormonal pattern and the hormonal activity of certain metabolites are described in detail. The structural formulae, serum concentrations, binding affinities to steroid receptors and serum binding globulins, and the relative potencies of the available estrogens and progestins are presented. Differences in the tissue-specific effects of the various compounds and regimens and their potential implications with the risks and benefits of hormone replacement therapy are discussed. INTRODUCTION The aim of any hormonal treatment of postmen- tance of pharmacological knowledge for an opausal women is not to restore the physiological optimal use of hormone therapy.
    [Show full text]
  • Selective Estrogen Receptor Modulator Raloxifene As a Possible Regulator of Arginine Vasopressin
    Case Report ISSN: 2574 -1241 DOI: 10.26717/BJSTR.2019.17.002969 Selective Estrogen Receptor Modulator Raloxifene as a Possible Regulator of Arginine Vasopressin Denise Börzsei1, Renáta Szabó1,2, Alexandra Hoffmann1, Krisztina Kupai1, Anikó Magyariné Berkó1, Csaba Varga1 and Anikó Pósa1,2* 1Department of Physiology, Anatomy and Neuroscience, Faculty of Science and Informatics, Hungary 2Department of Physiology, Anatomy and Neuroscience, Interdisciplinary Excellence Centre, Hungary *Corresponding author: Anikó Pósa, Department of Physiology, Anatomy and Neuroscience, Szeged, Hungary ARTICLE INFO abstract Received: April 08, 2019 Estrogen (E2) and raloxifene (RAL) have positive impact on the cardiovascular system throughout the regulation of blood pressure. In this present study we investigated how E2 Published: April 18, 2019 whether low-dose E2 monotherapy or RAL treatment change the AVP content compared Citation: Denise B, Renáta S, Alex- deficit influences the level of arginine vasopressin (AVP) in plasma. We also investigated andra H, Krisztina K, Anikó Pósa. Se- AVP compared to control group. However, administration of E2 and RAL in three different lective Estrogen Receptor Modulator dosesto hormone evoked deficient a decrease state. in theThe concentrationlack of E2 caused of AVP a significantin plasma. increaseIn addition, in the an levelinverse of Raloxifene as a Possible Regulator of correlation was found between the dose of RAL and AVP levels. These results indicate that Arginine Vasopressin. vasopressin expression is regulated
    [Show full text]